Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.
Sharing Clinical Data: Why
publishing studies with negative
or non-conclusive results is
important for patient’s safety.
P...
2
Goals of pharmacovigilance
• To improve patient care and safety in relation to the use of
medicines, and all medical and...
3
Impact of Adverse events
New EU
Pharmacovigilance
Legislation
Adverse events are important risk for public health and ha...
4
New PV legislation since 2012
• Adverse drug reactions are preventable in majority of cases
• Small improvements will ha...
Why publishing/disclosing
more Clinical Trials.
6
Clinical Studies are the 5th largest source of AE reporting
Often overlaps with reports from health professionals
FDA Ad...
7
Pharmacovigilance During Clinical Trial Phases
Pharmacovigilance: Ensuring the Safe Use of Medicines - WHO Policy Perspe...
8
History, Policies and Laws about Clinical Trials
• 1997: Congress Passes Law (FDAMA) Requiring Trial Registration
• 2000...
10
11
Number of registered studies with posted results over time
12
Number of published articles indexed in Medline
13
14
Bias in the non publication of clinical trials.
David K. Vawdrey, George Hripcsak, Publication bias in clinical trials ...
What did it bring,
pros and cons
16
BMJ 2011;342:d1250
17
Challenges of Detecting Adverse drug reactions in Clinical trials
Eichler, H.-G., Pignatti, F., Flamion, B., Leufkens, ...
18
To Share or Not to Share.
Pros Cons
Suppressing null results can
put patients at risk.
Issue of patient consent and
con...
19
To Share (or Not to Share).
• Better examples to educate and
motivate young scientist.
• Increased proportion of trials...
What is being done about it.
21
From Publishing:
• Public Library of Science (PLOS)
• Requires authors to make all data underlying the findings describ...
22
From Publishing, Elsevier
• Many or our medical journals already require registration of clinical
trials in a public tr...
23
From Publishing, Elsevier
• Disclosure of results before publication
• Presentation of data at a scientific meeting, as...
24
Making All Research Data Available
Publishing Open Access Journal publishing less impactful and negative
results
25
From Pharmaceutical companies:
• GlaxoSmithKline
• Provides access to de-identified patient-level data from its sponsor...
Conclusion and perspectives.
27
In summary
Clinical studies contain significant amount of information on
safety and efficacy of medicine
A significant ...
28
Conclusion and Questions to Consider
• Is more data always better ?
– Multiplicity of repository/sources to consult.
– ...
Thank you!
Any questions?
Nächste SlideShare
Wird geladen in …5
×

Clinical data sharing: why publishing negative and less impactful results is important for patient safety

1.047 Aufrufe

Veröffentlicht am

Clinical data sharing: why publishing negative and less impactful results is important for patient safety
Clinical trials are essential in drug development and are the cornerstone for getting a medicinal product authorized for marketing, because clinical trials investigate efficacy and drug safety. When the results of clinical trials are published, they can be informative to health care professionals, policy makers, media and the general public. But not all trial results are conclusive or significant, and many trials show that drugs are ineffective. These results often do not get published, either because these results are not suitable for a journal or because the researcher does not think these results are worth publishing. Due to the fact that inconclusive and insignificant results are not published, we are facing a publication bias towards positive results. During this webinar the speaker will demonstrate why publishing negative and less impactful results of clinical trials, as in Elsevier’s newly launched Open Access Journal ‘Contemporary Clinical Trials Communications’ reduces publication bias and is important for patient safety.

Veröffentlicht in: Gesundheit & Medizin
  • See how I make over $7,293 a month from home doing REAL online jobs!  http://t.cn/AisJWCv6
       Antworten 
    Sind Sie sicher, dass Sie …  Ja  Nein
    Ihre Nachricht erscheint hier
  • Unlock Her Legs is your passage way to a life full of loving and sex... read more ... ➤➤ http://scamcb.com/unlockher/pdf
       Antworten 
    Sind Sie sicher, dass Sie …  Ja  Nein
    Ihre Nachricht erscheint hier
  • My special guest's 3-Step "No Product Funnel" can be duplicated to start earning a significant income online. ■■■ https://tinyurl.com/y3ylrovq
       Antworten 
    Sind Sie sicher, dass Sie …  Ja  Nein
    Ihre Nachricht erscheint hier
  • Earn $90/day Working Online. You won't get rich, but it is going to make you some money! ♣♣♣ http://scamcb.com/ezpayjobs/pdf
       Antworten 
    Sind Sie sicher, dass Sie …  Ja  Nein
    Ihre Nachricht erscheint hier

Clinical data sharing: why publishing negative and less impactful results is important for patient safety

  1. 1. Sharing Clinical Data: Why publishing studies with negative or non-conclusive results is important for patient’s safety. Presented by: Pascal Hua Customer Consultant Date: 09 February 2016
  2. 2. 2 Goals of pharmacovigilance • To improve patient care and safety in relation to the use of medicines, and all medical and paramedical interventions • to improve public health and safety in relation to the use of medicines; • To contribute to the assessment of benefit, harm, effectiveness and risk of medicines, encouraging their safe, rational and more effective (including cost-effective) use; • To promote understanding, education and clinical training in pharmacovigilance and its effective communication to health professionals and the public.
  3. 3. 3 Impact of Adverse events New EU Pharmacovigilance Legislation Adverse events are important risk for public health and have major economic impact - 5% of all EU hospital admissions are due to adverse drug reactions - ADRs the fifth most common cause of hospital deaths (197,000 deaths per year) ~197k Deaths annually ~5k Lives saved annually Highlights form the World Drug Safety Congress Europe Held in London, UK, 10-11 September 2014. http://www.fishawack-archimed.com/Newsletters/Fishawack_Archimed_Safety_Reports_Issue1.pdf
  4. 4. 4 New PV legislation since 2012 • Adverse drug reactions are preventable in majority of cases • Small improvements will have major impact, meaning small improvements saves lot of patients lives • Relatively “easy” to save money in area of healthcare >> New PV legislation in EU implemented since 2012 (still ongoing)
  5. 5. Why publishing/disclosing more Clinical Trials.
  6. 6. 6 Clinical Studies are the 5th largest source of AE reporting Often overlaps with reports from health professionals FDA Adverse Event Reporting System (FAERS) Quarterly Data Files, Q2 and Q3 2013 Reported adverse events by report source, Q2 & Q3 2013 N = 34,469 unique events Overlap of adverse events sourced from literature by reporting sources, Q2 & Q3 2013 N = 4,691 unique events
  7. 7. 7 Pharmacovigilance During Clinical Trial Phases Pharmacovigilance: Ensuring the Safe Use of Medicines - WHO Policy Perspectives on Medicines, No. 009, October 2004 (2004; 6 pages)
  8. 8. 8 History, Policies and Laws about Clinical Trials • 1997: Congress Passes Law (FDAMA) Requiring Trial Registration • 2000: NIH National Library of Medicine releases ClinicalTrials.gov website • 2005: International Committee of Medical Journal Editors Requires Trial Registration • 2006: World Health Organization Establishes Trial Registration Policy • 2008: Clinical Trials.gov Releases Results Database • 2008: Declaration of Helsinki Revision Promotes Trial Registration and Results Dissemination • 2013: EMA Expands Clinical Trial Database to include Summary Results • 2014: Notice of proposed Rulemaking (NPRM) for FDAAA 801 Issued for Public Comment • 2014: NIH Draft Policy on Registration and Results Submission of NIH- Funded Clinical Trials Issued for Public Comment • 2015: National Cancer Institute Issues Clinical Trial Access Policy
  9. 9. 10
  10. 10. 11 Number of registered studies with posted results over time
  11. 11. 12 Number of published articles indexed in Medline
  12. 12. 13
  13. 13. 14 Bias in the non publication of clinical trials. David K. Vawdrey, George Hripcsak, Publication bias in clinical trials of electronic health records, Journal of Biomedical Informatics, Volume 46, Issue 1, February 2013, Pages 139-141.
  14. 14. What did it bring, pros and cons
  15. 15. 16 BMJ 2011;342:d1250
  16. 16. 17 Challenges of Detecting Adverse drug reactions in Clinical trials Eichler, H.-G., Pignatti, F., Flamion, B., Leufkens, H., Breckenridge, A. Balancing early market access to new drugs with the need for benefit/ risk data: A mounting dilemma (2008) Nature Reviews Drug Discovery, 7 (10), pp. 818-826 Myocardial Infarction
  17. 17. 18 To Share or Not to Share. Pros Cons Suppressing null results can put patients at risk. Issue of patient consent and confidentiality. Increased rigor and transparency of data management and analysis. Dissemination of incorrect or misleading analyses. More secondary analyses available for authorship. Persons bent on discrediting publishing work may perform rogue analyses. Junior investigators have more opportunities for trial- based analyses. Losing first authorship opportunity for junior investigators Academic credit assigned to data sets. Loss of publishing potential by academic clinical trialists.
  18. 18. 19 To Share (or Not to Share). • Better examples to educate and motivate young scientist. • Increased proportion of trials that are published. • Accelerate the publication speed of clinical trial research. • Fulfilling promise to participants of benefiting others.
  19. 19. What is being done about it.
  20. 20. 21 From Publishing: • Public Library of Science (PLOS) • Requires authors to make all data underlying the findings described in their manuscript fully available without restriction. For studies involving human participants, data must be handled so as not to compromise participant’s privacy. http://journals.plos.org/plosone/s/data-availability • British Medical Journal: • Requires all authors of drug or device clinical trials to provide detailed scientific study data to anyone with a reasonable request, whether or not the work is funded by the pharmaceutical industry. http://www.bmj.com/content/350/bmj.h2373
  21. 21. 22 From Publishing, Elsevier • Many or our medical journals already require registration of clinical trials in a public trials registry at or before the time of first patient enrollment as a condition for publication. • Leading the field in data sharing: • One of the first publisher to endorse the Joint Declaration of Data Citation Principle. https://www.force11.org/group/joint-declaration-data-citation- principles-final • Encouraging authors to include data DOI when relevant. • Linking to datasets within articles.
  22. 22. 23 From Publishing, Elsevier • Disclosure of results before publication • Presentation of data at a scientific meeting, as a poster, abstract, orally, on a CD, or as an abstract on the web does not conflict with submission to The Lancet • As a member journal of the International Committee for Medical Journal Editors, The Lancet does not regard results that are posted in the same clinical trials registry in which primary registration resides as prior publication, if the results are presented in the form of a brief structured abstract or table (<500 words; see Lancet 2007; 369: 1909-11). However, presentation of results in other circumstances (eg, investors’ meetings) is discouraged and could jeopardise consideration of the manuscript • http://www.thelancet.com/lancet/information-for-authors/disclosure- of-results.
  23. 23. 24 Making All Research Data Available Publishing Open Access Journal publishing less impactful and negative results
  24. 24. 25 From Pharmaceutical companies: • GlaxoSmithKline • Provides access to de-identified patient-level data from its sponsored clinical trials subject to review and oversight by an independent review panel. http://www.gsk.com/en-gb/research/sharing-our-research/patient- level-data/ • Now joined by Astellas, Bayer, Boehringer Ingelheim, Eisai, Lilly, Novartis, Roche, Sanofi, Takeda, UCB and ViiV Healthcare. https://www.clinicalstudydatarequest.com/
  25. 25. Conclusion and perspectives.
  26. 26. 27 In summary Clinical studies contain significant amount of information on safety and efficacy of medicine A significant number of clinical trial stay unpublished Effort from all sides are happening to fill this gap.
  27. 27. 28 Conclusion and Questions to Consider • Is more data always better ? – Multiplicity of repository/sources to consult. – Data/information mining... (Indexing structure, text mining). • Issues in normalization of the conditions and the reporting for data interpretation.
  28. 28. Thank you! Any questions?

×